07:00 , Aug 3, 2016 |  BC Extra  |  Company News

Roche returning rights to Inovio's HBV vaccine

Inovio Pharmaceuticals Inc. (NASDAQ:INO) said Roche (SIX:ROG; OTCQX:RHHBY) is terminating a 2013 deal and is returning exclusive, worldwide rights to Inovio's hepatitis B vaccine INO-1800 . Inovio expects data in 2H17 from an open-label Phase...
07:00 , Oct 26, 2015 |  BioCentury  |  Strategy

Collaborating on combos

As oncologists and drug developers converge on the idea that combination therapies built on a backbone of PD-L1 or PD-1 inhibitors could lead to cures for some cancers, or keep them at bay for years,...
07:00 , Sep 16, 2013 |  BC Week In Review  |  Company News

Inovio, Roche deal

Inovio granted Roche exclusive, worldwide rights to prostate cancer vaccine INO-5150 and hepatitis B vaccine INO-1800 , as well as use of Inovio's Cellectra electroporation technology to deliver the vaccines. Roche also has an option...
00:54 , Sep 11, 2013 |  BC Extra  |  Company News

Inovio licenses preclinical immunotherapy vaccines to Roche

Inovio Pharmaceuticals Inc. (NYSE-M:INO) granted Roche (SIX:ROG; OTCQX:RHHBY) exclusive, worldwide rights to prostate cancer vaccine INO-5150 and hepatitis B vaccine INO-1800, as well as use of Inovio's Cellectra electroporation technology to deliver the vaccines. Roche...
08:00 , Feb 14, 2011 |  BC Week In Review  |  Clinical News

Inovio preclinical data

In mice, Inovio's SynCon DNA prostate cancer vaccine delivered with the company's electroporation system induced strong prostate specific antigen (PSA) and prostate-specific membrane antigen ( PSMA )-specific cellular immune responses at 1 week after the...